Richard C Ragin

Title: Richard C. Ragin: Innovator in Tumor Treatment

Introduction

Richard C. Ragin is a notable inventor based in Brayton, MA (US). He has made significant contributions to the field of medical science, particularly in the treatment of tumors. With a total of 2 patents, Ragin's work focuses on innovative methods for utilizing Mullerian Inhibiting Substance (MIS) in cancer therapy.

Latest Patents

Ragin's latest patents include groundbreaking applications for the use of MIS in treating certain tumors. One patent discusses the treatment of tumors using an effective amount of the glycoprotein MIS. This application also covers the treatment of tumors through the use of the C-terminal fragment of MIS. Furthermore, it addresses DNA sequences encoding this fragment, vectors containing the DNA sequence, and transformed host cells capable of producing the C-terminal fragment. The application also explores gene therapy treatments aimed at inhibiting the growth of specific tumors. Another patent focuses on a method for purifying MIS, utilizing immunoaffinity chromatography to achieve a purity level of up to 95%. This method effectively removes contaminating enzymes and inhibitors, ensuring a high-quality MIS product.

Career Highlights

Richard C. Ragin is associated with The General Hospital Corporation, where he continues to advance his research and innovations. His work has the potential to significantly impact cancer treatment methodologies.

Collaborations

Ragin has collaborated with esteemed colleagues such as Patricia K. Donahoe and Tai Wai Chin, contributing to the advancement of research in tumor treatment.

Conclusion

Richard C. Ragin's innovative work in the field of tumor treatment through the application of Mullerian Inhibiting Substance showcases his dedication to medical science. His patents reflect a commitment to improving therapeutic options for patients facing cancer.